Sfoglia per AUTORE
ZHANG S
Collezione AOU Città della Salute di Torino
Items : 3
The presence of intraductal carcinoma of prostate is a risk factor for poor pathologic response in men with high-risk prostate cancer receiving neoadjuvant therapy. in Urologic oncology / Urol Oncol. 2024 Mar;42(3):67.e9-67.e15. doi: 10.1016/j.urolonc.2023.11.018. Epub 2024 Jan 17.
2024
AOU Città della Salute di Torino
AOU Città della Salute di Torino
Guo H; Zhang S; Zhuang J; Marra G; Peng S; Fu Y; Chen M; Wang B; Qiu X;
Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer: a Chinese, multicenter, real-world cohort study. in Translational lung cancer research / Transl Lung Cancer Res. 2023 Nov 30;12(11):2229-2244. doi: 10.21037/tlcr-23-577. Epub 2023 Oct 26.
2023
AOU Città della Salute di Torino
AOU Città della Salute di Torino
Chen X; Zhang S; Gu Y; Tang Y; Mu X; Qin J; Yang X; He M; Liu Y; Zhong W; Gao J; Chen M; Zhao J; Gao X; Liu J; Zhang H; Shi Y; Zhao D; Shen F; Liu X; Zhang D; Pang L; Meng Q; Guo Y; Zhang Y; Li W; Xing P; Cheng Y; Xin T; et alii...
Androgen deprivation therapy plus abiraterone or docetaxel as neoadjuvant therapy for very-high-risk prostate cancer: a pooled analysis of two phase II trials. in Frontiers in pharmacology / Front Pharmacol. 2023 Jun 26;14:1217303. doi: 10.3389/fphar.2023.1217303. eCollection 2023.
2023
AOU Città della Salute di Torino
AOU Città della Salute di Torino
Xu L; Qiu X; Marra G; Zhang S; Lyu X; Huang H; Fu Y; Zhang S; Wang Y; Zhuang J; Guo H;